Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
Gajewski TF, Louahed J, Brichard VG. Gajewski TF, et al. Among authors: brichard vg. Cancer J. 2010 Jul-Aug;16(4):399-403. doi: 10.1097/PPO.0b013e3181eacbd8. Cancer J. 2010. PMID: 20693853 Review.
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG. Ulloa-Montoya F, et al. Among authors: brichard vg. J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715562 Clinical Trial.
GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development.
Brichard VG, Lejeune D. Brichard VG, et al. Vaccine. 2007 Sep 27;25 Suppl 2:B61-71. doi: 10.1016/j.vaccine.2007.06.038. Vaccine. 2007. PMID: 17916463 Review.
Biological and clinical developments in melanoma vaccines.
Marchand M, Brichard V, van Baren N, Coulie PG. Marchand M, et al. Expert Opin Biol Ther. 2001 May;1(3):497-510. doi: 10.1517/14712598.1.3.497. Expert Opin Biol Ther. 2001. PMID: 11727521 Review.
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P. Saiag P, et al. Among authors: brichard vg. Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502712 Free PMC article. Clinical Trial.
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease.
Brichard VG, Lejeune D. Brichard VG, et al. Expert Opin Biol Ther. 2008 Jul;8(7):951-68. doi: 10.1517/14712598.8.7.951. Expert Opin Biol Ther. 2008. PMID: 18549325 Review.
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Marchand M, et al. Int J Cancer. 1999 Jan 18;80(2):219-30. doi: 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>;2-s. Int J Cancer. 1999. PMID: 9935203 Clinical Trial.
Melanoma vaccines: achievements and perspectives.
Brichard VG, Gérard C. Brichard VG, et al. Forum (Genova). 2003;13(2):144-54; quiz 189. Forum (Genova). 2003. PMID: 14732881 Review.
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG. Vansteenkiste J, et al. Among authors: brichard vg. J Clin Oncol. 2013 Jul 1;31(19):2396-403. doi: 10.1200/JCO.2012.43.7103. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715567 Clinical Trial.
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Szmania S, et al. Among authors: brichard vg. J Immunother. 2007 Nov-Dec;30(8):847-54. doi: 10.1097/CJI.0b013e318158fcff. J Immunother. 2007. PMID: 18049337
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page